Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc repurchased 555,000 ordinary shares on 24 October 2025 through BNP Paribas SA under its non‑discretionary buyback agreement. The company paid a volume‑weighted average price of 1,619.90p per share, within a range of 1,597.50p to 1,638.50p, and will hold the shares as treasury stock.
Since 30 September 2025, GSK has bought 6,282,500 ordinary shares as part of the programme. After this transaction, GSK holds 253,747,344 shares in treasury and has 4,061,673,442 shares in issue (excluding treasury), which is also the total number of voting rights. The company confirms the percentage of voting rights attributable to treasury shares is 6.25 per cent.
GSK plc repurchased 555,000 ordinary shares on 24 October 2025 through BNP Paribas SA under its non‑discretionary buyback agreement. The company paid a volume‑weighted average price of 1,619.90p per share, within a range of 1,597.50p to 1,638.50p, and will hold the shares as treasury stock.
Since 30 September 2025, GSK has bought 6,282,500 ordinary shares as part of the programme. After this transaction, GSK holds 253,747,344 shares in treasury and has 4,061,673,442 shares in issue (excluding treasury), which is also the total number of voting rights. The company confirms the percentage of voting rights attributable to treasury shares is 6.25 per cent.
GSK announced US FDA approval of Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including a PI and an IMID.
The approval is supported by phase III DREAMM-7, where the BVd combination cut the risk of death by 51% (HR 0.49; 95% CI: 0.32–0.76) and delivered a median progression-free survival of 31.3 months (95% CI: 23.5–NR) versus 10.4 months (95% CI: 7.0–13.4) for a daratumumab-based triplet (HR 0.31; 95% CI: 0.21–0.47). Safety was broadly consistent with known profiles.
Blenrep is described as the only anti-BCMA agent accessible across community settings and will be available under a new streamlined REMS. Follow-up for overall survival in DREAMM-7 and -8 continues, with data expected in early 2028, and the phase III DREAMM-10 first-line study is underway.
GSK announced US FDA approval of Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including a PI and an IMID.
The approval is supported by phase III DREAMM-7, where the BVd combination cut the risk of death by 51% (HR 0.49; 95% CI: 0.32–0.76) and delivered a median progression-free survival of 31.3 months (95% CI: 23.5–NR) versus 10.4 months (95% CI: 7.0–13.4) for a daratumumab-based triplet (HR 0.31; 95% CI: 0.21–0.47). Safety was broadly consistent with known profiles.
Blenrep is described as the only anti-BCMA agent accessible across community settings and will be available under a new streamlined REMS. Follow-up for overall survival in DREAMM-7 and -8 continues, with data expected in early 2028, and the phase III DREAMM-10 first-line study is underway.
GSK plc repurchased 366,000 ordinary shares on 23 October 2025 under its existing buyback programme via BNP Paribas SA. The purchases were made between 1,640.00p and 1,657.50p per share, with a volume‑weighted average price of 1,648.10p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 5,727,500 shares. Following this transaction, GSK holds 253,192,344 shares in treasury and has 4,062,224,575 shares in issue (excluding treasury). Total voting rights are 4,062,224,575. The percentage of voting rights attributable to treasury shares is 6.23%.
GSK plc repurchased 366,000 ordinary shares on 23 October 2025 under its existing buyback programme via BNP Paribas SA. The purchases were made between 1,640.00p and 1,657.50p per share, with a volume‑weighted average price of 1,648.10p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 5,727,500 shares. Following this transaction, GSK holds 253,192,344 shares in treasury and has 4,062,224,575 shares in issue (excluding treasury). Total voting rights are 4,062,224,575. The percentage of voting rights attributable to treasury shares is 6.23%.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 248,000 ordinary shares on 22 October 2025 at a volume‑weighted average price of 1,644.38p (range: 1,625.00p–1,655.00p). The shares will be held as treasury shares and the transaction forms part of GSK’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,361,500 shares. Following this purchase, GSK holds 252,826,344 shares in treasury and has 4,062,590,575 shares in issue (excluding treasury), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.22%.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 248,000 ordinary shares on 22 October 2025 at a volume‑weighted average price of 1,644.38p (range: 1,625.00p–1,655.00p). The shares will be held as treasury shares and the transaction forms part of GSK’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,361,500 shares. Following this purchase, GSK holds 252,826,344 shares in treasury and has 4,062,590,575 shares in issue (excluding treasury), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.22%.
GSK reported positive pivotal phase III results for a next‑generation, low‑carbon version of its Ventolin (salbutamol) metered dose inhaler using propellant HFA‑152a. The data show therapeutic equivalence and a comparable safety profile to the current HFA‑134a formulation, supporting regulatory submissions with launch expected from 2026.
GSK notes approximately 300 million salbutamol MDIs are sold globally each year and that, if approved, the new inhaler has the potential to reduce greenhouse gas emissions by 92% per inhaler. The company added that its salbutamol MDI currently accounts for close to 45% of its total global carbon footprint.
GSK reported positive pivotal phase III results for a next‑generation, low‑carbon version of its Ventolin (salbutamol) metered dose inhaler using propellant HFA‑152a. The data show therapeutic equivalence and a comparable safety profile to the current HFA‑134a formulation, supporting regulatory submissions with launch expected from 2026.
GSK notes approximately 300 million salbutamol MDIs are sold globally each year and that, if approved, the new inhaler has the potential to reduce greenhouse gas emissions by 92% per inhaler. The company added that its salbutamol MDI currently accounts for close to 45% of its total global carbon footprint.
GSK plc reported a share buyback transaction executed via BNP Paribas SA on 21 October 2025, purchasing 250,000 ordinary shares at prices between 1,635.00p and 1,650.00p, with a volume-weighted average price of 1,642.48p. The shares will be held as Treasury shares and the purchase forms part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,113,500 ordinary shares. Following this transaction, GSK holds 252,578,344 shares in treasury and has 4,062,838,575 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed that treasury-held ordinary shares represent 6.22% of voting rights.
GSK plc reported a share buyback transaction executed via BNP Paribas SA on 21 October 2025, purchasing 250,000 ordinary shares at prices between 1,635.00p and 1,650.00p, with a volume-weighted average price of 1,642.48p. The shares will be held as Treasury shares and the purchase forms part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,113,500 ordinary shares. Following this transaction, GSK holds 252,578,344 shares in treasury and has 4,062,838,575 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed that treasury-held ordinary shares represent 6.22% of voting rights.
GSK plc filed a Form 6-K announcing headline results from the INFRONT-3 trial of latozinemab in frontotemporal dementia due to progranulin mutation (FTD-GRN). The drug achieved a statistically significant effect on the biomarker co-primary endpoint, increasing plasma progranulin (PGRN), but did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data have not highlighted major concerns, and deeper analyses are ongoing.
Based on these results, GSK will discontinue the open-label extension portion of INFRONT-3 and the continuation study for latozinemab. Full results will be presented at an upcoming medical congress. GSK and Alector have collaborated on progranulin-elevating antibodies since July 2021, sharing development responsibilities and costs after Phase 2 proof-of-concept.
GSK plc filed a Form 6-K announcing headline results from the INFRONT-3 trial of latozinemab in frontotemporal dementia due to progranulin mutation (FTD-GRN). The drug achieved a statistically significant effect on the biomarker co-primary endpoint, increasing plasma progranulin (PGRN), but did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data have not highlighted major concerns, and deeper analyses are ongoing.
Based on these results, GSK will discontinue the open-label extension portion of INFRONT-3 and the continuation study for latozinemab. Full results will be presented at an upcoming medical congress. GSK and Alector have collaborated on progranulin-elevating antibodies since July 2021, sharing development responsibilities and costs after Phase 2 proof-of-concept.
GSK reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine). After approval by the European Commission, expected in December 2025, the ready-to-use format would eliminate reconstitution of two separate vials, simplifying administration for healthcare professionals.
Shingrix has been approved in the EU since 2018 for adults 50+ and since 2020 for adults 18+ at increased risk of herpes zoster. The positive opinion is based on data confirming technical comparability between the prefilled syringe and the current presentation. Shingles affects approximately 1.7 million people in Europe each year.
GSK reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine). After approval by the European Commission, expected in December 2025, the ready-to-use format would eliminate reconstitution of two separate vials, simplifying administration for healthcare professionals.
Shingrix has been approved in the EU since 2018 for adults 50+ and since 2020 for adults 18+ at increased risk of herpes zoster. The positive opinion is based on data confirming technical comparability between the prefilled syringe and the current presentation. Shingles affects approximately 1.7 million people in Europe each year.
GSK plc repurchased 220,000 ordinary shares on 20 October 2025 as part of its existing buyback programme, executed via BNP Paribas SA. The shares will be held as treasury shares.
On the day, prices ranged from 1,615.00p to 1,637.00p, with a volume‑weighted average price of 1,628.13p. Since 30 September 2025, GSK has purchased 4,863,500 ordinary shares under this programme.
After this transaction, GSK holds 252,328,344 shares in treasury and has 4,063,088,575 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,088,575, and the percentage of voting rights attributable to treasury shares is 6.21%.
GSK plc repurchased 220,000 ordinary shares on 20 October 2025 as part of its existing buyback programme, executed via BNP Paribas SA. The shares will be held as treasury shares.
On the day, prices ranged from 1,615.00p to 1,637.00p, with a volume‑weighted average price of 1,628.13p. Since 30 September 2025, GSK has purchased 4,863,500 ordinary shares under this programme.
After this transaction, GSK holds 252,328,344 shares in treasury and has 4,063,088,575 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,088,575, and the percentage of voting rights attributable to treasury shares is 6.21%.
GSK plc reported positive pivotal Phase 3 PIVOT-PO results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs), including pyelonephritis. The trial was stopped early for efficacy and met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin based on overall response at the test-of-cure visit.
Oral tebipenem HBr (600 mg) achieved a 58.5% overall success rate (261/446) versus 60.2% for IV imipenem-cilastatin (500 mg; 291/483), with an adjusted treatment difference of −1.3% (95% CI: −7.5%, 4.8%). Clinical cure rates were 93.5% vs 95.2%, and microbiological responses were 60.3% vs 61.3%, respectively. The safety profile was generally similar to imipenem-cilastatin, with diarrhea and headache the most frequent, mild-to-moderate events.
GSK plans to work with US regulators to include these data in a filing in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem in the US for cUTIs, potentially providing a home-based treatment alternative.
GSK plc reported positive pivotal Phase 3 PIVOT-PO results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs), including pyelonephritis. The trial was stopped early for efficacy and met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin based on overall response at the test-of-cure visit.
Oral tebipenem HBr (600 mg) achieved a 58.5% overall success rate (261/446) versus 60.2% for IV imipenem-cilastatin (500 mg; 291/483), with an adjusted treatment difference of −1.3% (95% CI: −7.5%, 4.8%). Clinical cure rates were 93.5% vs 95.2%, and microbiological responses were 60.3% vs 61.3%, respectively. The safety profile was generally similar to imipenem-cilastatin, with diarrhea and headache the most frequent, mild-to-moderate events.
GSK plans to work with US regulators to include these data in a filing in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem in the US for cUTIs, potentially providing a home-based treatment alternative.